An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
A small company called Mountain Valley MD says it's making progress on a product they call Quicksome™, which is a way to deliver peptides under the tongue (sublingually). They announced initial formulation work — meaning early steps in creating stable, usable versions — for several peptides, and specifically mentioned BPC-157. This is a company update, not a large clinical trial or a regulatory approval. Peptides are short chains of amino acids — think of them as tiny bits of proteins. Some peptides can act like signals in the body, nudging tissues to do certain things. BPC-157 is one of those peptides that people talk about online and in some research circles; it was originally identified in stomach juice and has been studied mainly in lab animals for possible effects on healing and inflammation. Delivering a peptide sublingually means placing it under the tongue so it can be absorbed through the mouth lining instead of swallowed and broken down in the stomach. What the announcement actually says is that Mountain Valley MD has been working on formulations — the recipes and methods — to make several peptides stable and effective when given sublingually. They reported this initial lab and formulation work, not results from humans showing benefit or safety. The news is about manufacturing and delivery technique, not clinical proof. There’s no indication in the release that they completed large-scale testing or that health authorities have evaluated these products. Why this could matter is practical: many peptides are currently given by injection because they break down in the gut. If a safe and reliable sublingual form worked, it could make administration easier and more appealing to people who want to avoid needles. That could interest doctors, compounding pharmacies, and patients who already use peptide therapies. But remember, easier delivery only matters if the peptide actually does what people hope, and that has to be shown in good human studies. There are important caveats. BPC-157 and many other peptides are still largely unproven in humans; much of the research so far has been in animals or in very small, uncontrolled human reports. Compounded peptide products are not the same as FDA-approved medicines and aren’t regulated with the same level of evidence for safety and effectiveness. Side effects, long-term risks, and proper dosing may be unknown. People who are pregnant, breastfeeding, have serious health conditions, or are on multiple medications should be especially cautious and consult a licensed clinician. Bottom line: The company reports early progress in making under-the-tongue versions of several peptides, including BPC-157, but this is about formulation work — not proof that these products are safe or effective in people.
Source: Business Wire